Clinical trial
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary…
NCT00087529 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00087529 |
|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis |
| Official title | A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis |
| Acronym | OLYMPUS |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | placebo, rituximab |
| Enrollment | 439 |
| Start date | Jun 1, 2004 |
| Primary completion | Oct 1, 2007 |
| First posted | Jul 13, 2004 |
| Last update posted | Sep 9, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: